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Table 1: Staging & Prognostication

INTRODUCTION
Gestational trophoblastic neoplasia (GTN) refers to a
group of malignant conditions that develop due to
abnormal fertilization causing abnormal proliferation of
tissue. GTN is primarily treated with surgical evacuation
of the underlying proliferative tissue. Approximately half
of cases of GTN arise from molar pregnancy1. GTN
include invasive moles, choriocarcinomas, placentalsite trophoblastic tumors and epithelioid trophoblastic
tumors. The most common risk factors associated with
GTN are prior molar pregnancy, advanced maternal age
(>40 years of age), and Asian and Native American
ancestry2-4. Following evaluation of a molar pregnancy,
a post-molar GTN is diagnosed based on the
International Federation of Gynecology and Obstetrics
(FIGO) criteria, which includes elevated human
chorionic gonadotropin (hCG) levels, hCG levels
increasing >10% across three values recorded over a
two-week duration, weekly hCG level plateauing
(remaining within +/- 10% of the previous week’s results)
over a three-week period, and persistence of detectable
serum hCG for more than six months after molar
evacuation 5. A pathologic diagnosis of prior molar
pregnancy by curettage with increased hCG levels also
would be acceptable for diagnosis. According to the
World Health Organization scoring system of GTN,
factors including age, antecedent pregnancy, interval
months from index pregnancy, pretreatment HCG,
largest tumor size, site and number of metastases and
previous failed chemotherapy help stratify the risk of
patients and determine the type of treatment (table 1).

CASE REPORT
A 30 year-old female with a history of hypertension and
chronic sinus tachycardia was found to have a complete
molar pregnancy at the time of her 8-week ultrasound.
A subsequent D&C was performed, and D&C pathologic
findings demonstrated an invasive mole. She was found
to have a hCG level of 7,000. One week later, her hCG
was 15,387. The following week, her hCG was found to
be 23,883. A pelvic ultrasound demonstrated findings
consistent with thickened, heterogeneous and
hypervascular endometrium with cystic areas, consistent
with possible residual or recurrent molar pregnancy;
however, a mass was never seen on imaging. Given her

34 | The Medicine Forum, Volume 22 5

I

Disease confined to uterus

II

GTN extends outside of uterus but is limited
to the genital structures (adnexa, vagina,
broad ligament)

III

GTN extends to lungs without known genital
tract involvement

IV

All other metastatic sites

pathologic findings and serum values, she was classified
as a low-risk GTN. Between July 2018 to August 2019,
she was treated for her low-risk GTN with a regimen
including methotrexate (MTX) 80 mg SQ three days a
week alternating with leucovorin. She completed 19
cycles of methotrexate and achieved normalization of
hCG levels with 3 normal values recorded (table 2).
However, increasing hCG levels two months after
cessation of methotrexate led to concern for residual
disease. As such, she was referred to our center for a
second opinion. She was classified as FIGO stage I with
a WHO score of 6 points, due to: time frame of 12
months since index pregnancy, baseline hCG and
previous utilization of single drug (table 1). Her serum
hCG increased to 110, leading to the resumption of MTX.
She initially responded well to retreatment with MTX,
demonstrating undetectable HCG levels for almost three
months. After three months, her hCG again began to
increase while on treatment (table 2). Possible treatment
options at that point included actinomycin-D, EMA/CO,
avelumab and radical hysterectomy. The patient had
completed child bearing and elected to undergo a
radical abdominal hysterectomy- bilateral salpingectomy.
Post-surgical pathology ultimately demonstrated a
gestational trophoblastic tumor, most consistent with
choriocarcinoma invading into the myometrium. Her
post-operative HCG was undetectable.

Table 2: Clinical Course
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salvaged by further cisplatin-based chemotherapy and
surgery. For low risk GTN patients who are resistant to
single-agent MTX or Act D, preliminary data from a phase
II multicenter, cohort trial investigating the anti-PDL-L1
antibody avelumab has shown promise, with 8 out of 15
patients demonstrating 8 months of complete response10.
Due to this promising data, many ongoing clinical trials
in the low-risk GTN population include immunotherapy
as a single agent or in addition to MTX (NCT03135769,
NCT04303884).
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DISCUSSION
Complete hydatidiform mole and choriocarcinoma are
rare, distinct disease processes with characteristic
histologic and clinical features. In North America, there is
a 0.1% incidence of molar pregnancy in all pregnancies.
Although rare, low-risk GTN due to molar pregnancy is
almost always curable with single-agent chemotherapy.
A 2016 Cochrane database meta-analysis compared
chemotherapy regimens for low-risk GTN and concluded
that although pulsed actinomycin-D may achieve high
primary cure with less chance of treatment failure in
women with low-risk GTN, worsening serious adverse
events were seen with this regimen than with a
methotrexate regimen 6 . Actinomycin-D (Act D) may be
used for patients who cannot tolerate methotrexate due
to side effects of hyperemesis, alopecia and tissue
extravasation. In a clinical trial in low-risk GTN, patients
with a hCG value >4000 IU/L were found to respond
poorly to Act D 7. Alternatively, a study examining 1072
low-risk GTN patients with WHO score <6 demonstrated
that hysterectomy as a first-line treatment is effective
without salvage chemotherapy in approximately 82% of
these patients. However, it was also concluded that young
patients, such as the case mentioned above, should be
considered for single-agent chemotherapy instead of
surgery-only, as chemotherapy has been almost always
curative while maintaining fertility8,9.
In high-risk or refractory GTN, consideration can be given
to combination chemotherapy with cyclophosphamide
and vincristine (EMA/CO). The cumulative 5 year survival
rate for these patients is greater than 85%, and patients
who developed resistance to this regimen generally were

Although complete molar pregnancy related GTN is a
generally rare condition, low and high-risk tumors have a
high cure rate with chemotherapy. In the above case, our
patient had low-risk GTN, however, given she had an
increase in hCG upon cessation of single-agent
methotrexate she had evidence of persistent disease or
possible relapse. Treatment options for this included
hysterectomy, which the patient elected to undergo.
Hysterectomy led to undetectable post-operative HCG
levels, and surgical pathology proved that her underlying
etiology was choriocarcinoma.
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